Cost–effectiveness of the prophylactic HPV vaccine: An application to the Netherlands taking non-cervical cancers and cross-protection into account

• Published in: Vaccine Vol. 31; no. 37; pp. 3922 - 3927
• Main Authors: Luttjeboer, J, Westra, T.A, Wilschut, J.C, Nijman, H.W, Daemen, T, Postma, M.J
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 20.08.2013; Elsevier; Elsevier Limited
• Subjects: Allergy and Immunology; Anus; Anus Neoplasms - prevention & control; Anus Neoplasms - virology; Applied microbiology; Biological and medical sciences; Cervical cancer; Child; cost effectiveness; Cost-Benefit Analysis; Cost–effectiveness analysis; Cross Protection; Female; Fundamental and applied biological sciences. Psychology; girls; HPV; Human papillomavirus; Human papillomavirus 16 - pathogenicity; Human papillomavirus 18 - pathogenicity; Humans; Immunization; Immunization Programs - economics; Medical research; Medical sciences; Microbiology; Models, Economic; Netherlands - epidemiology; Non-cervical cancers; Oropharyngeal Neoplasms - economics; Oropharyngeal Neoplasms - prevention & control; Oropharyngeal Neoplasms - virology; oropharynx; Papillomavirus Infections - economics; Papillomavirus Infections - prevention & control; Papillomavirus Vaccines - economics; Papillomavirus Vaccines - immunology; prices; quality-adjusted life year; screening; Sensitivity analysis; Tumors; uterine cervical neoplasms; Uterine Cervical Neoplasms - economics; Uterine Cervical Neoplasms - epidemiology; vaccination; Vaccination - economics; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); vagina; Vaginal Neoplasms - economics; Vaginal Neoplasms - prevention & control; vulva; Vulvar Neoplasms - economics; Vulvar Neoplasms - prevention & control; Vulvar Neoplasms - virology; women; Netherlands; Europe; Western Europe; Non-cervical cancers; Cross-protection; Cost–effectiveness analysis; HPV; Cross protection; Vaccine; Malignant tumor; Female genital diseases; Prevention; Cost-effectiveness analysis; Uterine cervix diseases; Cervical cancer; Cancer; Cost efficiency analysis
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2013.06.044

Highlights • We examine the cost–effectiveness of the bivalent HPV-vaccine. • Cross-protection and protection against non-cervical cancers are taken into account. • The cost–effectiveness ratio (CER) was €5815 per quality adjusted life year. • The CER falls far below the Dutch willingness-to-pay threshold of €20,000/QALY. • The CER is sensitive to vaccine price, cost and disutility of cervical cancer.